8/23/2013 5:14 PM ET|
'Sunshine Act' is making doctors nervous
The new law requires pharmaceutical companies to publicly disclose dollars they've given to physicians.
The so-called Physican Payments Sunshine Act went into effect earlier this month, and it applies to the manufacturers of pharmaceuticals, medical devices and biologicals that take part in federal health care programs. As The Wall Street Journal reports, that information will be posted on a publicly accessible website beginning in September 2014.
The drug industry has come under criticism for some time for the hundreds of millions of dollars it hands out annually to doctors in the form of gifts and fees. According to The Journal, drug giant Pfizer (PFE) paid out $173.2 million to U.S. health care professionals last year.
A lot of that funding comes in the form of consulting and speaking fees, sometimes tens of thousands of dollars at a time. But some physicians say the new disclosure regulations are making them review their relationships with the pharmaceutical industry.
"I'll continue to weigh the benefits and the negatives, and I think the Sunshine Act and the public reporting of all this stuff makes us think about that," John Mandrola, a Louisville, Ky.-based cardiologist, told The Journal. "And I think that's a good thing."
Dr. Mandrola said he has been paid around $2,000 this year by medical device makers to speak at some engagements. But he has also become more cautious about accepting such fees, and told newspaper that he now "avoids industry reps visiting his office, believing he can get information on new drugs elsewhere."
The one major exception to the new law is payments or other compensation made by businesses to doctors speaking at some accredited, continuing medical education events, but only if the sponsoring corporation doesn't select or directly pay the event's speaker.
The AMA also says doctors have the right to review these new disclosure reports and to challenge what they consider false, inaccurate or misleading data. Some industry critics, however, hope the new regulations will force physicians to think twice about the sometimes too-comfortable relationships many have with pharmaceutical and other companies.
"The idea is that transparency will encourage doctors to evaluate whether these are appropriate relationships with companies or not," Daniel Carlat, a psychiatrist and director of the prescription project at the Pew Charitable Trusts, told The Journal.
Copyright © 2014 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
[BRIEFING.COM] The stock market punctuated July with a broad-based retreat that sent the S&P 500 lower by 2.0% with all ten sectors ending in the red. The benchmark index posted a monthly decline of 1.5%, while the Russell 2000 (-2.3%) underperformed to end the month lower by 6.1%.
To get a better feel for what led to today's retreat, we'd like to look back to Wednesday, when the market had ample reason to rally, but did not. Instead, it ended basically flat after a sloppy day of ... More
More Market News
Investors are anxious to see if hiring can maintain its strong pace in the second half of the year.
MUST-SEE ON MSN
- Video: Easy DIY smoked meats at home
A charcuterie master shares his process for cold-smoking meat at home.
- Jetpacks about to go mainstream
- Weird things covered by home insurance
- Bing: 70 percent of adults report 'digital eye strain'